Aurinia completes Kezar acquisition at $6.96 per share plus CVR

Aurinia Pharmaceuticals Inc.
KEZAR LIFE SCIENCES, INC.

Aurinia Pharmaceuticals Inc.

AUPH

0.00

KEZAR LIFE SCIENCES, INC.

KZR

0.00
  • Aurinia completed acquisition of Kezar Life Sciences via tender offer priced at USD 6.96 per share in cash plus one contingent value right.
  • Offer expired May 8, 2026 with 5,927,580 shares tendered, representing about 80.24% of outstanding shares.
  • Merger closed May 11, 2026, leaving Kezar as a wholly owned subsidiary of Aurinia’s US unit.
  • Outstanding Kezar options vested at closing, with in-the-money awards converted into cash based on spread to cash price plus CVRs; out-of-the-money options were cancelled.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-020402), on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.